TSXV:CLAS.H - Post by User
Post by
Captainblkon Dec 18, 2019 7:43pm
![](https://assets.stockhouse.com/kentico-cms/0342-00/images/Sprite.svg#id_Post_Views_Icon)
29 Views
Post# 30470689
Second Quarter Operating Costs 2019
Second Quarter Operating Costs 2019Research and development expenses in Q3 2019 decreased to approximately $1.0 million, from approximately $1.9 million in Q3 2018. This decrease was due primarily to a decrease in subcontracted R&D costs relating to the Companys Phase 2 clinical trial in the prevention of acute GVHD, which is nearing completion. General and administrative expenses in Q3 2019 were approximately $1.1 million, compared to approximately $800,000 in Q3 2018. This increase in general and administrative expenses was primarily due to a loss on investments of approximately $180,000 in Q3 2019 that the Company incurred in connection with the Companys decision to not proceed with the acquisition of a CBD extraction business, as well as an increase in legal and professional fees in the amount of approximately $80,000 in Q3 2019.